Awardee OrganizationTHE TRUSTEES OF THE STEVENS INSTITUTE OF TECHNOLOGY
Description
Abstract Text
DESCRIPTION (provided by applicant): Bacteria in biofilm show unique physiological characteristics that are much different from planktonic cultured phenotypes. One of the most important features of bacterial biofilms is their resistance to antimicrobial agents and the host immune system attacks. Bacteria living in biofilms can exhibit up to 1,000 time greater resistance to antibiotics than planktonic bacteria. Biofilm associated nosocomial (hospital acquired) infection and disease is currently the fourth leading cause of death in the United States, behind only heart disease, cancer and stroke. Regardless what anti-biofilm methods are used, the success rates are very limited and biofilms will nevertheless form on implanted devices. In most cases, biofilm related infections can only be cured by a high cost and undesirable procedure through the removal of the implants. In this project, we propose to fight against biofilm from a new direction by directly dealing with attached bacteria and formed biofilms. We propose to construct functional surfaces which can interrupt the formation of biofilm architecture. Our hypothesis is that biofilms formed on these functional surfaces with damaged biofilm architectures may not be able to develop antibiotic resistance. Bacteria in such biofilms may maintain antibiotic sensitivity and can be killed by ordinary antibiotic treatment. Three board objectives of this project are to 1) construct surfaces with desired structures and functions; 2) study biofilm formation dynamics and morphologies on functionalized surfaces; 3) test the antibiotic sensitivity of "biofilms" on functionalized surfaces and study sensitizing mechanisms using different antibiotic treatment approaches and fitting data with established mathematic models. PUBLIC HEALTH RELEVANCE: Biofilm Growth on Functionalized Surfaces Narrative Bacteria can attach to the surfaces of implant devices and grow into bacteria clusters (called biofilms). Unlike free bacteria, bacterial in biofilms can hardly be killed by ordinary antibiotic treatment. Biofilm associated infection and disease is currently the fourth leading cause of death in the United States, behind only heart disease, cancer, and stroke. The goal of this research is to develop new types of surfaces to prevent biofilm related infections and diseases.
Public Health Relevance Statement
Biofilm Growth on Functionalized Surfaces
Narrative
Bacteria can attach to the surfaces of implant devices and grow into bacteria clusters (called biofilms).
Unlike free bacteria, bacterial in biofilms can hardly be killed by ordinary antibiotic treatment. Biofilm
associated infection and disease is currently the fourth leading cause of death in the United States, behind
only heart disease, cancer, and stroke. The goal of this research is to develop new types of surfaces to
prevent biofilm related infections and diseases.
NIH Spending Category
No NIH Spending Category available.
Project Terms
AccountingAdoptedAffectAntibiotic ResistanceAntibiotic TherapyAntibioticsAntimicrobial ResistanceArchitectureBacteriaBacterial AdhesionBiocompatible MaterialsBloodBody FluidsCause of DeathCell surfaceCellsCharacteristicsChargeDataDevelopmentDiagnosticDiseaseDropsEnvironmentEventExcisionExhibitsFigs - dietaryGoalsGrowthHeart DiseasesImmune systemImplantInfectionLeftLifeLiquid substanceMalignant NeoplasmsMathematicsMedicalMethodsMicrobial BiofilmsModelingModificationMolecularMolecular ConformationMontanaMorbidity - disease rateMorphologyNosocomial InfectionsOperative Surgical ProceduresPhenotypePhysiologicalPolymersPreventionProceduresProsthesisResearchResistance developmentSolidStrokeStructureSurfaceTestingTimeUnited StatesUniversitiesantimicrobial drugaqueouscell killingcostdesigndesign and constructionexperiencefight againstimplantable devicekillingsmicrobialpreventpublic health relevancesuccessweb site
National Institute of Allergy and Infectious Diseases
CFDA Code
701
DUNS Number
064271570
UEI
JJ6CN5Y5A2R5
Project Start Date
15-May-2009
Project End Date
30-April-2011
Budget Start Date
15-May-2009
Budget End Date
30-April-2010
Project Funding Information for 2009
Total Funding
$231,571
Direct Costs
$150,000
Indirect Costs
$81,571
Year
Funding IC
FY Total Cost by IC
2009
National Institute of Allergy and Infectious Diseases
$231,571
Year
Funding IC
FY Total Cost by IC
Sub Projects
No Sub Projects information available for 1R21AI078176-01A1
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 1R21AI078176-01A1
Patents
No Patents information available for 1R21AI078176-01A1
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 1R21AI078176-01A1
Clinical Studies
No Clinical Studies information available for 1R21AI078176-01A1
News and More
Related News Releases
No news release information available for 1R21AI078176-01A1
History
No Historical information available for 1R21AI078176-01A1
Similar Projects
No Similar Projects information available for 1R21AI078176-01A1